BIRC5 and colorectal cancer: In a phase I study, an HLA-A24-restricted antigenic peptide, Survivin 2B80-88, which is recognised by CD8+ cytotoxic T-lymphocytes, was used to vaccinate patients with recurrent colorectal cancer.